



## Post Authorisation Assessments

For details of post authorisation assessments prior to 1<sup>st</sup> January 2021,  
please refer to the [EMA](#) website.

### Onsior 5 mg Tablets for Dogs Vm 52127/5023

02 February 2026	Minor changes to an approved test procedure for the active substance. Deletion of a non-significant specification parameter of an active substance. Change in qualitative or quantitative composition of the immediate packaging for the active substance.
19 December 2025	Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible. Up to 10-fold increase change in batch size (including batch size ranges) of an active substance intermediate. Downscaling down up to 10-fold change in batch size (including batch size ranges) of an active substance intermediate.
10 June 2025	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
21 December 2023	Addition of a new supplier of a starting material used during the manufacturing process of the active substance.
12 October 2023	One-off alignment of the product information with version 9.0 of the QRD templates.
10 February 2023	Change in the specification parameters and/or limits of the immediate packaging of the finished product.